Dendreon seeks a buyer as it files for bankruptcy

10 November 2014

US biotech firm Dendreon (Nasdaq: DNDN) has filed voluntary petitions under Chapter 11 of the Bankruptcy Code in the US Bankruptcy Court as part of a far-reaching financial restructuring agreement.

The company announced today that it has reached agreements on the terms of a financial restructuring with certain holders of the company's 2.875% Convertible Senior Notes due 2016, representing around 84% of the $620 million aggregate principal amount of the 2016 Notes. Under the terms of the agreements, the financial restructuring may take the form of a stand-alone recapitalization or a sale of the company or its assets.

Prostate cancer treatment Provenge (sipuleucel-T) is the company’s only product. The company said the transactions under the agreements will enable continued delivery of Provenge without disruption or impact to access for providers and appropriate patients.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK